JP2019501194A5 - - Google Patents

Download PDF

Info

Publication number
JP2019501194A5
JP2019501194A5 JP2018535324A JP2018535324A JP2019501194A5 JP 2019501194 A5 JP2019501194 A5 JP 2019501194A5 JP 2018535324 A JP2018535324 A JP 2018535324A JP 2018535324 A JP2018535324 A JP 2018535324A JP 2019501194 A5 JP2019501194 A5 JP 2019501194A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
opioid
antagonist
opioid antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018535324A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019501194A (ja
JP7061568B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/012452 external-priority patent/WO2017120417A1/en
Publication of JP2019501194A publication Critical patent/JP2019501194A/ja
Publication of JP2019501194A5 publication Critical patent/JP2019501194A5/ja
Application granted granted Critical
Publication of JP7061568B2 publication Critical patent/JP7061568B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018535324A 2016-01-08 2017-01-06 オピオイド新生児薬物離脱症候群の処置及び予防 Active JP7061568B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662276691P 2016-01-08 2016-01-08
US62/276,691 2016-01-08
PCT/US2017/012452 WO2017120417A1 (en) 2016-01-08 2017-01-06 Treatments and prevention of opioid neonatal abstinence syndrome

Publications (3)

Publication Number Publication Date
JP2019501194A JP2019501194A (ja) 2019-01-17
JP2019501194A5 true JP2019501194A5 (https=) 2020-01-23
JP7061568B2 JP7061568B2 (ja) 2022-04-28

Family

ID=59274434

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018535324A Active JP7061568B2 (ja) 2016-01-08 2017-01-06 オピオイド新生児薬物離脱症候群の処置及び予防

Country Status (8)

Country Link
US (3) US10925870B2 (https=)
EP (1) EP3400066B1 (https=)
JP (1) JP7061568B2 (https=)
CN (1) CN108778423A (https=)
AU (1) AU2017206041B2 (https=)
CA (1) CA3010609A1 (https=)
DK (1) DK3400066T3 (https=)
WO (1) WO2017120417A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019199704A1 (en) * 2018-04-09 2019-10-17 Katana Pharmaceuticals, Inc. Oxytocin compositions and methods of use
CN113573711A (zh) * 2019-01-04 2021-10-29 伊瑟治疗公司 治疗药物或酒精依赖性的方法
US10653690B1 (en) * 2019-07-09 2020-05-19 Orexo Ab Pharmaceutical composition for nasal delivery
CN117915916A (zh) * 2021-07-06 2024-04-19 伊瑟治疗公司 低剂量纳曲醇和其用途
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010049375A1 (en) * 2000-03-15 2001-12-06 Wolfgang Sadee Neutral antagonists and use thereof in treating drug abuse
SI1646328T1 (sl) * 2003-07-25 2008-02-29 Euro Celtique Sa Zdravljenje pri odvajanju od odvisnosti
KR20070086334A (ko) * 2004-11-16 2007-08-27 리머릭 뉴로사이언스즈, 인크. 통증을 치료하기 위한 방법 및 조성물
US8748448B2 (en) 2007-10-18 2014-06-10 Aiko Biotechnology Combination analgesic employing opioid agonist and neutral antagonist
EP2214672B1 (en) 2007-10-18 2012-10-17 Aiko Biotechnology Combination analgesic employing opioid and neutral antagonist
WO2009079489A1 (en) * 2007-12-17 2009-06-25 The Ohio State University Research Foundation Methods for screening of opioid receptor neutral antagonists and inverse agonists and uses thereof
US9226918B2 (en) * 2008-12-04 2016-01-05 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating or preventing narcotic withdrawal symptoms

Similar Documents

Publication Publication Date Title
Labianca et al. Adverse effects associated with non-opioid and opioid treatment in patients with chronic pain
JP2019501194A5 (https=)
JP2009525343A5 (https=)
JP2017510607A5 (https=)
Sturn et al. Low-dose naltrexone: a new therapy option for complex regional pain syndrome type I patients
JP2016505050A5 (https=)
JP2016520114A5 (https=)
CR20240015A (es) COMPOSICIÓN FARMACÉUTICA CON ANTAGONISTA DEL RECEPTOR DE MINERALOCORTICOIDES Y SU USO (Divisional Expediente 2019-203)
Patel et al. Opioids for pain after oral surgery
EP2830605A1 (en) A combination medicament comprising phenylephrine and paracetamol
KR101978459B1 (ko) 조루증 치료용 약학 조성물 및 조루증 치료 방법
JP6940265B2 (ja) 止瀉剤組成物
Linn et al. Peripherally restricted μ-opioid receptor antagonists: a review
JP6940264B2 (ja) 止瀉剤組成物
Yeomanson et al. Paediatric palliative care: intravenous methylnaltrexone relieves constipation
KR101598283B1 (ko) 안전성 및 효능이 증가된 월경통 완화 또는 치료용 복합제 조성물
NZ744112B2 (en) Treatments and prevention of opioid neonatal abstinence syndrome
CN109966291A (zh) 化合物sb216763在制备预防和/或治疗脑血管疾病的药物中的应用及其药物组合物
NZ744112A (en) Treatments and prevention of opioid neonatal abstinence syndrome
CN103316346B (zh) 治疗癫痫的药物组合物
JP6753661B2 (ja) 止瀉剤組成物
Hellwig et al. The Role of Methylnaltrexone in Opioid-induced Constipation.
JP6676326B2 (ja) 止瀉用の漢方製剤
Chiou et al. The use of transdermal fentanyl in cancer pain—a compliance study of outpatients in Taiwan
Jerome Check et al. COMPLETE RESOLUTION OF THE BURNING MOUTH SYNDROME IN A NORMAL ESTROGENIC WOMAN FOLLOWING TREATMENT WITH AMPHETAMINES